Oral anticoagulation in advanced chronic kidney disease and atrial fibrillation was associated with decreased 1-year risk of thromboembolic events and death (P<0.001) but increased major bleeding.
Cohort
Does oral anticoagulation reduce thromboembolic events and death in patients with advanced chronic kidney disease and atrial fibrillation?
In patients with advanced chronic kidney disease and atrial fibrillation, oral anticoagulation reduces thromboembolic events and death but increases the risk of major bleeding at 1 year.
p-value: p=<0.001
Background: The net benefit of oral anticoagulation (OAC) with vitamin K antagonists or direct oral anticoagulants in patients with advanced chronic kidney disease and atrial fibrillation remains uncertain. Objectives: (including dialysis-treated patients) and atrial fibrillation. Methods: were identified in national Danish registers between 2010 and 2022. Initiation of OAC was identified based on redemption of a relevant prescription. One-year risks of thromboembolic event, major bleeding, and death associated with OAC and no treatment were computed and standardized to the distribution of risk factors in the sample based on hazards determined in multiple Cox regression models adjusted for age and sex. Results: < .001) for death, respectively. Conclusion: In a retrospective study on patients with advanced chronic kidney disease and atrial fibrillation, OAC was associated with overall decreased 1-year risk of thromboembolic event and death offset by increased 1-year risk of major bleeding.
Ballegaard et al. (Thu,) conducted a cohort in advanced chronic kidney disease and atrial fibrillation. Oral anticoagulation (OAC) vs. no treatment was evaluated on 1-year risk of thromboembolic event, major bleeding, and death (p=<0.001). Oral anticoagulation in advanced chronic kidney disease and atrial fibrillation was associated with decreased 1-year risk of thromboembolic events and death (P<0.001) but increased major bleeding.